Phoenix prepares for a digital future
This article was originally published in OTC Bulletin & The Rose Sheet
Digitalisation is becoming a key strategic focus for Phoenix, according to the firm’s chief executive officer Oliver Windholz.
You may also be interested in...
With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
CDER wants sponsors to use the NextGen Portal for electronic submission of promotional pieces to the Office of Prescription Drug Promotion, rather than sending in paper or physical media such as CDs; availability of this alternative pathway does not affect requirement for eCTD submission of some types of promotional materials starting in June 2021.